{"id":"tiotropium-formoterol-beclometasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"},{"rate":null,"effect":"Muscle cramps"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium is a long-acting muscarinic antagonist that blocks acetylcholine-mediated bronchoconstriction. Formoterol is a long-acting beta-2 adrenergic agonist that promotes bronchial smooth muscle relaxation. Beclometasone is an inhaled corticosteroid that reduces airway inflammation. Together, these three agents provide sustained bronchodilation and anti-inflammatory effects in a single inhaled formulation.","oneSentence":"This combination drug provides long-acting bronchodilation via tiotropium (anticholinergic) and formoterol (beta-2 agonist), plus anti-inflammatory action via beclometasone (inhaled corticosteroid) for maintenance treatment of chronic obstructive pulmonary disease and asthma.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:12:47.064Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"},{"name":"Asthma maintenance treatment"}]},"trialDetails":[{"nctId":"NCT04480242","phase":"","title":"Asthma Research in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2017-07-26","conditions":"Persistent Asthma, Asthma in Children, Asthma Exacerbation","enrollment":525},{"nctId":"NCT07058259","phase":"NA","title":"Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istanbul Medeniyet University","startDate":"2024-11-15","conditions":"COPD (Chronic Obstructive Pulmonary Disease), Acupuncture","enrollment":60},{"nctId":"NCT03290287","phase":"","title":"Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":26839},{"nctId":"NCT03662711","phase":"PHASE4","title":"Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease","status":"TERMINATED","sponsor":"Università degli Studi di Ferrara","startDate":"2018-11-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":843},{"nctId":"NCT02467452","phase":"PHASE3","title":"Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2015-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1479},{"nctId":"NCT01911364","phase":"PHASE3","title":"Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3686},{"nctId":"NCT04179461","phase":"PHASE2","title":"Personalized Treatment Algorithms for Difficult-to-treat Asthma","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-03-16","conditions":"Asthma in Children","enrollment":21},{"nctId":"NCT02676089","phase":"PHASE3","title":"TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-04-06","conditions":"Asthma","enrollment":1433},{"nctId":"NCT01656005","phase":"PHASE4","title":"Beta Blocker Therapy in Moderate to Severe COPD","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2012-08","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":18},{"nctId":"NCT03333018","phase":"","title":"A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22155},{"nctId":"NCT02790047","phase":"NA","title":"Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD","status":"UNKNOWN","sponsor":"Khon Kaen University","startDate":"2016-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":50},{"nctId":"NCT01466712","phase":"PHASE4","title":"Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function","status":"UNKNOWN","sponsor":"KU Leuven","startDate":"2011-11","conditions":"COPD, Emphysema, Small Airway Disease","enrollment":20},{"nctId":"NCT00668408","phase":"PHASE4","title":"LTOT in COPD Patients With Moderate Chronic Hypoxemia and Chronic Heart Failure","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2008-05","conditions":"Lung Diseases, Obstructive, Chronic Heart Failure, Chronic Hypoxemia","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inuvair (B10356)"],"phase":"marketed","status":"active","brandName":"Tiotropium + formoterol/beclometasone","genericName":"Tiotropium + formoterol/beclometasone","companyName":"KU Leuven","companyId":"ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug provides long-acting bronchodilation via tiotropium (anticholinergic) and formoterol (beta-2 agonist), plus anti-inflammatory action via beclometasone (inhaled corticosteroid) for maintenance treatment of chronic obstructive pulmonary disease and asthma. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}